Medtronic stock forecast trading desks note reduced short

Trading desks note reduced short interest as risk appetite returns. Overall, we would be extremely cautious before making any decision on Medtronic. As a result of its low ROE and lack of much reinvestment into the business, the company has seen a disappointing earnings growth rate. That being so, the latest industry analyst forecasts show that the analysts are expecting to see a huge improvement in the company's earnings growth rate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Galway, Ireland-based Medtronic plc ( MDT ) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients around the globe. With a market cap of $105.6 billion , the company operates through Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit segments. Medtronic stock forecast indicates potential upticks with EPS guidance reaffirmed at $5.10–$5.20 for FY